Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
uStudio Adds Three Top Technology Executives to Leadership Team
-
Sanford Heisler Sharp Announces Promotions & New Leadership Roles
-
Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases
-
Brand Managers at Top Pharmaceuticals Select Entatio.com for iVA Projects
-
3PEA International Names Al Negron Senior Vice President Business Development
-
ComplianceOnline Announces 2018 Seminar on Radiation Sterilization of Medical Products
-
FDA understates percentage of foreign-made medication sold in U.S.
-
76-Ton Airlift of Medicine and Medical Supplies Lands in Puerto Rico
-
Novartis delivered growth on top and bottom line in all divisions in Q3
-
ThromboGenics Business Update - Q3 2017
-
ThromboGenics Business Update - Q3 2017
-
New data shows astigmatism tends to worsen following cataract surgery with a standard monofocal IOL, while patient awareness about advanced technology treatment options is limited
-
Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals
-
Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL
-
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
-
ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US
-
ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US
-
ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting
-
ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting
-
On Tap Credit Union® Announces New Executive Appointments
-
Alcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaign
-
NY LASIK Laser Microsurgery Institute, With Locations in Manhattan, Brooklyn and Queens Offers the Next Generation for LASIK Using Topoguided Contoura Vision
-
Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development
-
ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
-
ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
-
U.S. Loyalty Marketing and Technology Firm Excentus Strengthens Consumer Data & Business Intelligence Capabilities for National Brands, Consumer Packaged Goods (CPG) Manufacturers and Convenience
-
Sanford Heisler Sharp Takes On Equifax In Tennessee
-
Sanford Heisler Sharp Takes On Equifax In Data Breach And Privacy Class Action
-
ThromboGenics Business Update - H1 2017
-
ThromboGenics Business Update - H1 2017
-
Akcea Therapeutics (AKCA) Names Michael MacLean as CFO
-
Akcea Expands Leadership Team in Preparation for First Commercial Launch
-
Novartis names drugs chief as CEO to deliver return to growth
-
NuVasive (NUVA) Announces New Organizational Structure; COO, CFO Resign
-
NuVasive Announces New Organizational Structure To Drive Growth And Profitability Goals
-
Morgan Stanley Double Upgrades Novartis (NVS) to Overweight
-
Largest Gathering of Medical Science Liaison Professionals in the World Will Meet at the Annual MSL Society Conference in Las Vegas, September 5-7
-
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
-
Dr. Sabri Markabi Joins MedinCell's Supervisory Board
-
Novartis (NVS): Raising PT To Account For New Pipeline Candidates - Leerink
-
Delphinus Appoints Global R&D Leader Bruno Dacquay as New Vice President of Engineering
-
Teva Announces Exclusive Launch of Generic Pataday® in the United States
-
New Alcon survey reveals that people are happier, more satisfied with their lives after cataract surgery
-
NuVasive Appoints Skip Kiil As Executive Vice President, International
-
Novartis CEO sees no need for big takeover
-
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
-
Alcon's ORA System(TM) with VerifEye(TM) Technology Now Available in Canada
-
Novartis has assets to sell, investors wary of what it might buy
-
FDAnews Announces -- Medical Devices: Making the Right Choice -- Your Case for Quality Webinar, Sponsored by Novartis and Tech-Clarity, June 8, 2017
-
Radius Health (RDUS) Confirms Jose Carmona as New CFO

